Infectious diseases in the critically ill patients

Journal of Pharmacy Practice

Volumn 24, Issue 1, 2011, Pages 35-43

  Martin, Steven J ^a   Yost, Raymond J ^b  

^a UNIVERSITY OF TOLEDO   (United States)

^b LEXINGTON VA MEDICAL CENTER   (United States)

Author keywords

Antimicrobial resistance; Bloodstream infection; Pharmacokinetics; Urinary tract infection; Ventilator associated pneumonia

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; AZTREONAM; CARBAPENEM; CARBAPENEMASE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN; CEPHAMYCIN; CLAVULANIC ACID; COLISTIN; CYTOCHROME P450; DAPTOMYCIN; DNA TOPOISOMERASE; ECHINOCANDIN; EXTENDED SPECTRUM BETA LACTAMASE; FLUCONAZOLE; LINEZOLID; METALLO BETA LACTAMASE; NITROFURANTOIN; OPIATE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFAMETHOXAZOLE; TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTERIAL VIRULENCE; BLOOD CULTURE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDEMIA; CANDIDIASIS; CENTRAL VENOUS CATHETER; CLOSTRIDIUM DIFFICILE INFECTION; CORTICOSTEROID THERAPY; CRITICALLY ILL PATIENT; DRUG ABSORPTION; DRUG MEGADOSE; ENDOCARDITIS; ENTEROBACTER; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL MOTILITY; GLUCURONIDATION; HOSPITAL INFECTION; HUMAN; INFECTION; INTENSIVE CARE UNIT; KIDNEY FAILURE; KLEBSIELLA; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MEMBRANE PERMEABILITY; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIDRUG RESISTANCE; NEOPLASM; NEUTROPENIA; OUTCOME ASSESSMENT; PARENTERAL NUTRITION; PNEUMONIA; PSEUDOMONAS AERUGINOSA; RENAL REPLACEMENT THERAPY; STOMACH PH; SULFATION; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 79953858086     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190010388906     Document Type: Article

References (53)

1. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323-2329.
2. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7): 1303-1310. (Pubitemid 32641789)
3. Marshall JC, Charbonney E, Gonzalez PD. The immune system in critical illness. Clin Chest Med. 2008;29(4):605-616.
4. Zilberberg MD, Shorr AF, Micek ST, et al. Antimicrobial therapy escalation and hospital mortality among patients with health-careassociated pneumonia: a single-center experience. Chest. 2008;134(5):963-968.
5. Kuti EL, Patel AA, Coleman CI. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. J Crit Care. 2008;23(1):91-100. (Pubitemid 351400347)
6. Micek ST, Lloyd AE, Ritchie DJ, et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005;49(4): 1306-1311. (Pubitemid 40463352)
7. Leclerq R. Epidemiological and resistance issues in multidrugresistant staphylococci and enterococci. Clin Microbiol Infect. 2009;15(3):224-231.
8. Popovich KJ, Weinstein RA, Hota B. Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin Infect Dis. 2008;46(6):787-794. (Pubitemid 351417176)
9. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest. 2003;124(5): 1789-1797. (Pubitemid 37433574)
10. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653-665.
11. Fisher K, Phillips C. The ecology, epidemiology and virulence of Enterococcus. Microbiology. 2009;155(pt 6):1749-1757.
12. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39(3):309-317. (Pubitemid 39050477)
13. Tacconelli E, Cataldo MA. Vancomycin-resistant enterococci (VRE): transmission and control. Int J Antimicrob Agents. 2008;31(2):99-106.
14. Eliopoulos GM.Microbiology of drugs for treating multiply drugresistant Gram-positive bacteria. J Infect. 2009;59(suppl 1): S17-S24.
15. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase producing bacteria. Lancet Infect Dis. 2009;9(4):228-236.
16. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010;65(6):1119-1125.
17. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother. 2009;64(suppl 1):i29-i36.
18. Paterson DL. Resistance in gram-negative bacteria: enterobacteriaceae. Am J Infect Control. 2006;34(5 suppl 1):S20-S28.
19. Hidron AI, Edwards JR, Patel J, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2006- 2007. Infect Control Hosp Epidemiol. 2008;29(11):996-1011.
20. Nguyen LH, Hsu DI, Ganapathy V, et al. Reducing empirical use of fluoroquinolones for Pseudomonas aeruginosa infections improves outcome. J Antimicrob Chemother. 2008;61(3): 714-720. (Pubitemid 351321151)
21. Aarts MA, Hancock JN, Heyland D, et al. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care Med. 2008;36(1):108-117.
22. Heyland DK, Dodek P, Muscedere J, et al. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med. 2008;36(1):737-744.
23. Murray CK, Hospenthal DR. Acinetobacter infection in the ICU. Crit Care Clin. 2008;24(2):237-248. (Pubitemid 351400617)
24. Nicasio AM, Kuti JL, Nicolau DP. The current state of multidrugresistant Gram-negative bacilli in North America; Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2008;28(2):235-249. (Pubitemid 351206969)
25. Livermore DM, Hope R, Brick G, et al. Non-susceptibility trends among enterobacteriaceae frombacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother. 2008;62(suppl 2):ii41-ii54.
26. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum b-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and metaanalysis. J Antimicrob Chemother. 2007;60(5):913-920. (Pubitemid 47617735)
27. Rodriguez-Baño J, Navarro MD, Romero L, et al. Bacteremia due to extended-spectrum b-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis. 2006;43(11):1407-1414. (Pubitemid 44845640)
28. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48(5):503-535.
29. Boucher B, Wood G, Swanson J. Pharmacokinetic changes in critical illness. Crit Care Clin. 2006;22(2):255-271, vi.
30. Dasta JF, Boucher BA, Brophy GM, et al. Intravenous to oral conversion of antihypertensives: a toolkit for guideline development. Ann Pharmacother. 2010;44(9):1430-1447.
31. Tortorici M, Kochanek P, Poloyac S. Effects of hypothermia on drug disposition, metabolism, and response: a focus of hypothermia-mediated alterations on the cytochrome P450 enzyme system. Crit Care Med. 2007;35(9):2196-2204. (Pubitemid 47326460)
32. van den Broek M, Groenendaal F, Egberts A, et al. Effects of hypothermia on pharmacokinetics and pharmacodynamics: a systematic review of preclinical and clinical studies. Clin Pharmacokinet. 2010;49(5):277-294.
33. Iida Y, Nishi S, Asada A. Effect of mild therapeutic hypothermia on phenytoin pharmacokinetics. Ther Drug Monit. 2001;23(3): 192-197. (Pubitemid 32476543)
34. Satas S, Hoem N, Melby K, et al. Influence of mild hypothermia after hypoxia-ischemia on the pharmacokinetics of gentamicin in newborn pigs. Biol Neonate. 2000;77(1):50-57.
35. Lodise TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007; 44(3):357-363. (Pubitemid 46147617)
36. Cohen S, Gerding D, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431-455.
37. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388-416.
38. Singh N, Rogers P, Atwood C, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. 2000;162(2 pt 1):505-511. (Pubitemid 30647191)
39. Paul M, Benuri-Silbiger I, Soares-Weiser K, et al. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ. 2004; 328(7441):668.
40. Cometta A, Baumgartner J, Lew D, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother. 1994;38(6): 1309-1313. (Pubitemid 24170712)
41. Chastre J, Wolff M, Fagon J, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290(19):2588-2598. (Pubitemid 37443289)
42. Méan M, Marchetti O, Calandra T. Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care. 2008;12(1):204.
43. León C, Ruiz-Santana S, Saavedra P, et al. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med. 2009; 37(5):1624-1633.
44. Playford E, Lipman J, Sorrell T. Management of invasive candidiasis in the intensive care unit. Drugs. 2010;70(7):823-839.
45. Hooton TM, Bradley BF, Cardenas DD. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(5):625-663.
46. Laupland KB, Bagshaw SM, Gregson DB, et al. Intensive care unit-acquired urinary tract infections in a regional critical care system. Crit Care. 2005;9(2):R60-R65.
47. Clec'h C, Schwebel C, Francais A. et al. Does catheter-associated urinary tract infection increase mortalityt in critically ill patients? Infect Control Hosp Epidemiol. 2007;28(12):1367-1373. (Pubitemid 351412086)
48. Januel JM, Harbarth S, Allard R, et al. Estimating attributable mortality due to nosocomial infections acquired in intensive care units. Infect Control Hosp Epidemiol. 2010;31(4):399-394.
49. Nicolle LE. Catheter-related urinary tract infection. Drugs Aging. 2005;22(8):627-639. (Pubitemid 41138976)
50. Centers for Disease Control and Prevention (CDC). Monitoring hospital-acquired infections to promote patient safety-United States, 1990-1999. MMWR Morb Mortal Wkly Rep. 2000;49(8): 149-153.
51. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosisand management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1-45.
52. Garnacho-Montero J, Aldabo-Pallas T, Palomar-Martinez M, et al. Risk factors and prognosis of catheter-related bloodstream infection in the critically ill: a multicenter study. Intensive Care Med. 2008;34(12):2185-2193.
53. Karchmer AW. Bloodstream infections: the problem and the challenge. Int J Antimicob Agents. 2009;34(suppl 4):S2-S4.